Not checkedNot checked for notices yet.
Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose
Hurkmans Coen W, Schuring Danny
Radiation Oncology · 2008
doi:10.1186/1748-717x-3-21 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Purpose</p> <p>To investigate the influence of inhomogeneity corrections on stereotactic treatment plans for non-small cell lung cancer and determine the dose delivered to the PTV and OARs.</p> <p>Materials and methods</p> <p>For 26 patients with stage-I NSCLC treatment plans were optimized with unit density (UD), an equivalent pathlength algorithm (EPL), and a collapsed-cone (CC) algorithm, prescribing 60 Gy to the PTV. After optimization the first two plans were recalculated with the more accurate CC algorithm. Dose parameters were compared for the three different optimized plans. Dose to the target and OARs was evaluated for the recalculated plans and compared with the planned values.</p> <p>Results</p> <p>For the CC algorithm dose constraints for the ratio of the 50% isodose volume and the PTV, and the V<sub>20 Gy </sub>are harder to fulfill. After recalculation of the UD and EPL plans large variations in the dose to the PTV were observed. For the unit density plans, the dose to the PTV varied from 42.1 to 63.4 Gy for individual patients. The EPL plans all overestimated the PTV dose (average 48.0 Gy). For the lungs, the recalculated V<sub>20 Gy </sub>was highly correlated to the planned value, and was 12% higher for the UD plans (R<sup>2 </sup>= 0.99), and 15% lower for the EPL plans (R<sup>2 </sup>= 0.96).</p> <p>Conclusion</p> <p>Inhomogeneity corrections have a large influence on the dose delivered to the PTV and OARs for SBRT of lung tumors. A simple rescaling of the dose to the PTV is not possible, implicating that accurate dose calculations are necessary for these treatment plans in order to prevent large discrepancies between planned and actually delivered doses to individual patients.</p>
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.